The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease

Nature Reviews Neuroscience

Volumn 17, Issue 6, 2016, Pages 383-395

  Haeusler, Aaron R ^a   Donnelly, Christopher J ^b   Rothstein, Jeffrey D ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME 9 OPEN READING FRAME 72; PROTEIN; RNA; UNCLASSIFIED DRUG; C9ORF72 PROTEIN, HUMAN;

AMYOTROPHIC LATERAL SCLEROSIS; CHROMOSOME 9; DEGENERATIVE DISEASE; FRONTOTEMPORAL DEMENTIA; GAIN OF FUNCTION MUTATION; GENOMIC INSTABILITY; LOSS OF FUNCTION MUTATION; NUCLEOCYTOPLASMIC TRANSPORT; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; REVIEW; STRESS; TRINUCLEOTIDE REPEAT; ANIMAL; GENETICS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BASE SEQUENCE; HUMANS; NEURODEGENERATIVE DISEASES; PROTEINS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84965072119     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn.2016.38     Document Type: Review

References (148)

1. Renton A. E, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21 linked ALS-FTD. Neuron 72 257-268 (2011).
2. DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p linked FTD and ALS. Neuron. 72, 245-256 (2011).
3. Majounie E, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 11, 323-330 (2012).
4. Zhang D, Iyer L. M, He F, & Aravind L. Discovery of novel DENN proteins: implications for the evolution of eukaryotic intracellular membrane structures and human disease. Front. Genet. 3, 283 (2012).
5. Levine T. P, Daniels R. D, Gatta A. T, Wong L. H, & Hayes M. J. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics. 29, 499-503 (2013).
6. Allaire P. D, et al. The Connecdenn DENN domain: a GEF for Rab35 mediating cargo-specific exit from early endosomes. Mol. Cell. 37, 370-382 (2010).
7. Marat A. L, Dokainish H, & McPherson P. S. DENN domain proteins: regulators of Rab GTPases. J. Biol. Chem. 286, 13791-13800 (2011).
8. Ciura S, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann. Neurol. 74, 180-187 (2013).
9. Suzuki N, et al. The mouse C9ORF72 ortholog is enriched in neurons known to degenerate in ALS and FTD. Nat. Neurosci. 16, 1725-1727 (2013).
10. Kim M. S, et al. A draft map of the human proteome. Nature 509 575-581 (2014).
11. Xiao S, et al. Isoform-specific antibodies reveal distinct subcellular localizations of C9orf72 in amyotrophic lateral sclerosis. Ann. Neurol. 78, 568-583 (2015).
12. Farg M. A, et al. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum. Mol. Genet. 23, 3579-3595 (2014).
13. Donnelly C. J, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 80, 415-428 (2013).
14. Almeida S, et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 126, 385-399 (2013).
15. Gijselinck I, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-Amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 11 54-65 (2012).
16. Belzil V. V, et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol. 126, 895-905 (2013).
17. Waite A. J, et al. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol. Aging. 35, 1779.e5-1779.e13 (2014).
18. Haeusler A. R, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 507 195-200 (2014).
19. Xi Z, et al. Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am. J. Hum. Genet. 92, 981-989 (2013).
20. Sareen D, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl Med. 5, 208ra149 (2013).
21. van Blitterswijk M, et al. Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathol. 130, 863-876 (2015).
22. ORourke J. G, et al. C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron 88 892-901 (2015).
23. Grabczyk E, & Usdin K. The GAA TTC triplet repeat expanded in Friedreichs ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner. Nucleic Acids Res. 28, 2815-2822 (2000).
24. Ohshima K, Montermini L, Wells R. D, & Pandolfo M. Inhibitory effects of expanded GAA. TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J. Biol. Chem. 273, 14588-14595 (1998).
25. Parsons M. A, Sinden R. R, & Izban M. G. Transcriptional properties of RNA polymerase II within triplet repeat-containing DNA from the human myotonic dystrophy and fragile X loci. J. Biol. Chem. 273, 26998-27008 (1998).
26. Tornaletti S, Park-Snyder S, & Hanawalt P. C. G4 forming sequences in the non-Transcribed DNA strand pose blocks to T7 RNA polymerase and mammalian RNA polymerase II. J. Biol. Chem. 283, 12756-12762 (2008).
27. Li Y, et al. Expanded GAA repeats impede transcription elongation through the FXN gene and induce transcriptional silencing that is restricted to the FXN locus. Hum. Mol. Genet. 24, 6932-6943 (2015).
28. Liu C. R, et al. Spt4 is selectively required for transcription of extended trinucleotide repeats. Cell. 148, 690-701 (2012).
29. Batra R, Charizanis K, & Swanson M. S. Partners in crime: bidirectional transcription in unstable microsatellite disease. Hum. Mol. Genet. 19, R77-R82 (2010).
30. Zu T, et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl Acad. Sci. USA. 110, E4968-E4977 (2013).
31. Mori K, et al. Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 126, 881-893 (2013).
32. Core L. J, Waterfall J. J, & Lis J. T. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science. 322, 1845-1848 (2008).
33. Seila A. C, et al. Divergent transcription from active promoters. Science. 322, 1849-1851 (2008).
34. Bernstein E, & Allis C. D. RNA meets chromatin. Genes Dev. 19, 1635-1655 (2005).
35. Pelechano V, & Steinmetz L. M. Gene regulation by antisense transcription. Nat. Rev. Genet. 14, 880-893 (2013).
36. Chung D. W, Rudnicki D. D, Yu L, & Margolis R. L. A natural antisense transcript at the Huntingtons disease repeat locus regulates HTT expression. Hum. Mol. Genet. 20, 3467-3477 (2011).
37. Sopher B. L, et al. CTCF regulates ataxin 7 expression through promotion of a convergently transcribed, antisense noncoding RNA. Neuron. 70, 1071-1084 (2011).
38. Gascon E, & Gao F. B. The emerging roles of microRNAs in the pathogenesis of frontotemporal dementia-Amyotrophic lateral sclerosis (FTD-ALS) spectrum disorders. J. Neurogenet. 28, 30-40 (2014).
39. Freischmidt A, et al. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain. 137, 2938-2950 (2014).
40. Therrien M, Rouleau G. A, Dion P. A, & Parker J. A. Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in C. elegans. PLoS ONE. 8, e83450 (2013).
41. Wen X, et al. Antisense proline-Arginine RAN dipeptides linked to C9ORF72 ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 84, 1213-1225 (2014).
42. Lagier-Tourenne C, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl Acad. Sci. USA. 110, E4530-E4539 (2013).
43. Koppers M, et al. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann. Neurol. 78, 426-438 (2015).
44. Harms M. B, et al. Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis. Neurobiol. Aging. 34, 2234.e13-2234.e19 (2013).
45. Fratta P, et al. Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. Acta Neuropathol. 126, 401-409 (2013).
46. Peters O. M, et al. Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron. 88, 902-909 (2015).
47. Mizielinska S, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345 1192-1194 (2014).
48. Gendron T. F, et al. Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-Associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 126, 829-844 (2013).
49. Cooper-Knock J, et al. Antisense RNA foci in the motor neurons of C9ORF72 ALS patients are associated with TDP 43 proteinopathy. Acta Neuropathol. 130, 63-75 (2015).
50. Mizielinska S, et al. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol 126 845-857 (2013).
51. Gami P, et al. A 30 unit hexanucleotide repeat expansion in C9orf72 induces pathological lesions with dipeptide-repeat proteins and RNA foci, but not TDP 43 inclusions and clinical disease. Acta Neuropathol 130 599-601 (2015).
52. Todd P. K, & Paulson H. L. RNA-mediated neurodegeneration in repeat expansion disorders. Ann. Neurol. 67, 291-300 (2010).
53. Miller J. W, et al. Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy. EMBO J. 19, 4439-4448 (2000).
54. Cooper-Knock J, et al. Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain. 137, 2040-2051 (2014).
55. Mori K, et al. hnRNP A3 binds to GGGGCC repeats and is a constituent of p62 positive/TDP43 negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathol. 125, 413-423 (2013).
56. Xu Z, et al. Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc. Natl Acad. Sci. USA. 110, 7778-7783 (2013).
57. Prudencio M, et al. Distinct brain transcriptome profiles in C9orf72 associated and sporadic ALS. Nat. Neurosci. 18, 1175-1182 (2015).
58. Lee Y. B, et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 5, 1178-1186 (2013).
59. Zhang K, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 525, 56-61 (2015).
60. Zu T, et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl Acad. Sci. USA. 108, 260-265 (2011).
61. Todd P. K, et al. CGG repeat-Associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron. 78, 440-455 (2013).
62. Mori K, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 339, 1335-1338 (2013).
63. Ash P. E. A, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 77, 639-646 (2013).
64. Mackenzie I. R, et al. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol. 126, 859-879 (2013).
65. Mann D. M, et al. Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol. Commun. 1, 68 (2013).
66. Cleary J. D, & Ranum L. P. Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders. Curr. Opin. Genet. Dev. 26, 6-15 (2014).
67. Gomez-Deza J, et al. Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration. Acta Neuropathol. Commun. 3, 38 (2015).
68. Schludi M. H, et al. Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathol. 130, 537-555 (2015).
69. Gendron T. F, et al. Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathol. 130, 559-573 (2015).
70. Cooper-Knock J, et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain. 135, 751-764 (2012).
71. Baborie A, et al. Accumulation of dipeptide repeat proteins predates that of TDP 43 in frontotemporal lobar degeneration associated with hexanucleotide repeat expansions in C9ORF72 gene. Neuropathol. Appl. Neurobiol. 41, 601-612 (2014).
72. Chew J, et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP 43 pathology, neuronal loss, and behavioral deficits. Science. 348, 1151-1154 (2015).
73. Su Z, et al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-Associated defects in c9FTD/ALS. Neuron. 83, 1043-1050 (2014).
74. Devlin A. C, et al. Human iPSC-derived motoneurons harbouring TARDBP or C9ORF72 ALS mutations are dysfunctional despite maintaining viability. Nat. Commun. 6, 5999 (2015).
75. Wainger B. J, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 7, 1-11 (2014).
76. Wainger B. J, & Cudkowicz M. E. Cortical hyperexcitability in amyotrophic lateral sclerosis: C9orf72 repeats. JAMA Neurol. 72, 1235-1236 (2015).
77. Kwon I, et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 345, 1139-1145 (2014).
78. May S, et al. C9orf72 FTLD/ALS-Associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol 128 485-503 (2014).
79. Zhang Y. J, et al. Aggregation-prone c9FTD/ALS poly(GA) RAN-Translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 128, 505-524 (2014).
80. Yang D, et al. FTD/ALS-Associated poly(GR) protein impairs the Notch pathway and is recruited by poly(GA) into cytoplasmic inclusions. Acta Neuropathol. 130, 525-535 (2015).
81. Tran H, et al. Differential toxicity of nuclear RNA foci versus dipeptide repeat proteins in a Drosophila model of C9ORF72 FTD/ALS. Neuron. 87, 1207-1214 (2015).
82. Yamakawa M, et al. Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS. Hum. Mol. Genet. 24, 1630-1645 (2015).
83. Tsoi H, Lau T. C. K, Tsang S. Y, Lau K. F, & Chan H. Y. E. CAG expansion induces nucleolar stress in polyglutamine diseases. Proc. Natl Acad. Sci. USA. 109, 13428-13433 (2012).
84. Tao Z, et al. Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity. Hum. Mol. Genet. 24, 2426-2441 (2015).
85. Freibaum B. D, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 525, 129-133 (2015).
86. Jovicic A, et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 18, 1226-1229 (2015).
87. Woerner A. C, et al. Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA. Science. 351, 173-176 (2016).
88. Ling J. P, Pletnikova O, Troncoso J. C, & Wong P. C. TDP 43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 349, 650-655 (2015).
89. Wheeler T. M, et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature. 488, 111-115 (2012).
90. Miller T. M, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a Phase 1 randomised, first in man study. Lancet Neurol. 12, 435-442 (2013).
91. Keil J. M, et al. A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Mol. Ther. Nucleic Acids. 3, e174 (2014).
92. Yang W. Y, Wilson H. D, Velagapudi S. P, & Disney M. D. Inhibition of Non-ATG translational events in cells via covalent small molecules targeting RNA. J. Am. Chem. Soc. 137, 5336-5345 (2015).
93. Zamiri B, Reddy K, Macgregor R. B. Jr & Pearson C. E. TMPyP4 porphyrin distorts RNA G quadruplex structures of the disease-Associated r(GGGGCC)n repeat of the C9orf72 gene and blocks interaction of RNA-binding proteins. J. Biol. Chem. 289, 4653-4659 (2014).
94. Haines J. D, et al. Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination. Nat. Neurosci. 18, 511-520 (2015).
95. Winer L, et al. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol. 70, 201-207 (2013).
96. Liang P, et al. CRISPR/Cas9 mediated gene editing in human tripronuclear zygotes. Protein Cell. 6, 363-372 (2015).
97. Xi Z, et al. Jump from pre-mutation to pathologic expansion in C9orf72. Am. J. Hum. Genet. 96, 962-970 (2015).
98. Xi Z, et al. The C9orf72 repeat expansion itself is methylated in ALS and FTLD patients. Acta Neuropathol. 129, 715-727 (2015).
99. McMurray C. T. Mechanisms of trinucleotide repeat instability during human development. Nat. Rev. Genet. 11, 786-799 (2010).
100. Suh E, et al. Semi-Automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathol. 130, 363-372 (2015).
101. Gijselinck I, et al. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Mol. Psychiatry http://dx.doi.org/10.1038/.mp.2015.159 (2015).
102. Gallagher M. D, et al. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol. 127, 407-418 (2014).
103. van Blitterswijk M, et al. TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol. 127, 397-406 (2014).
104. Mirkin S. M. Expandable DNA repeats and human disease. Nature. 447, 932-940 (2007).
105. Orr H. T, & Zoghbi H. Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30, 575-621 (2007).
106. La Spada A. R, & Taylor J. P. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat. Rev. Genet. 11, 247-258 (2010).
107. Pearson C. E, Nichol Edamura K, & Cleary J. D. Repeat instability: mechanisms of dynamic mutations. Nat. Rev. Genet. 6, 729-742 (2005).
108. Dols-Icardo O, et al. Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Hum. Mol. Genet. 23, 749-754 (2014).
109. Nordin A, et al. Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD. Hum. Mol. Genet. 24, 3133-3142 (2015).
110. Aguilera A, & Garcia-Muse T. Causes of genome instability. Annu. Rev. Genet. 47, 1-32 (2013).
111. Lopez Castel A, Cleary J. D, & Pearson C. E. Repeat instability as the basis for human diseases and as a potential target for therapy. Nat. Rev. Mol. Cell Biol. 11, 165-170 (2010).
112. Kruisselbrink E, et al. Mutagenic capacity of endogenous G4 DNA underlies genome instability in FANCJ-defective C. elegans. Curr. Biol. 18, 900-905 (2008).
113. Ribeyre C, et al. The yeast Pif1 helicase prevents genomic instability caused by G quadruplex-forming CEB1 sequences in vivo. PLoS Genet. 5, e1000475 (2009).
114. Piazza A, et al. Genetic instability triggered by G quadruplex interacting Phen DC compounds in Saccharomyces cerevisiae. Nucleic Acids Res. 38, 4337-4348 (2010).
115. De S, & Michor F. DNA secondary structures and epigenetic determinants of cancer genome evolution. Nat. Struct. Mol. Biol. 18, 950-955 (2011).
116. Aghili L, Foo J, DeGregori J, & De S. Patterns of somatically acquired amplifications and deletions in apparently normal tissues of ovarian cancer patients. Cell Rep. 7, 1310-1319 (2014).
117. Koole W, et al. A polymerase Theta-dependent repair pathway suppresses extensive genomic instability at endogenous G4 DNA sites. Nat. Commun. 5, 3216 (2014).
118. van Kregten M, & Tijsterman M. The repair of G quadruplex-induced DNA damage. Exp. Cell Res. 329, 178-183 (2014).
119. Aguilera A. The connection between transcription and genomic instability. EMBO J. 21, 195-201 (2002).
120. Li X, & Manley J. L. Cotranscriptional processes and their influence on genome stability. Genes Dev. 20, 1838-1847 (2006).
121. Aguilera A, & Garcia-Muse T. R loops: from transcription byproducts to threats to genome stability. Mol. Cell. 46, 115-124 (2012).
122. Bhatia V, et al. BRCA2 prevents R loop accumulation and associates with TREX 2 mRNA export factor PCID2. Nature. 511, 362-365 (2014).
123. Skourti-Stathaki K, & Proudfoot N. J. A double-edged sword: R loops as threats to genome integrity and powerful regulators of gene expression. Genes Dev 28 1384-1396 (2014).
124. Lin Y, Dent S. Y, Wilson J. H, Wells R. D, & Napierala M. R loops stimulate genetic instability of CTG. CAG repeats. Proc. Natl Acad. Sci. USA. 107, 692-697 (2010).
125. Nakamori M, Pearson C. E, & Thornton C. A. Bidirectional transcription stimulates expansion and contraction of expanded (CTG) (CAG) repeats. Hum. Mol. Genet. 20, 580-588 (2011).
126. Reddy K, et al. Processing of double-R loops in (CAG). (CTG) and C9orf72 (GGGGCC).(GGCCCC) repeats causes instability. Nucleic Acids Res. 42, 10473-10487 (2014).
127. Moreira M. C, et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat. Genet. 36, 225-227 (2004).
128. Chen Y. Z, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet. 74, 1128-1135 (2004).
129. Martin-Tumasz S, & Brow D. A. S. cerevisiae Sen1 helicase domain exhibits 5 to 3 helicase activity with a preference for translocation on DNA rather than RNA. J. Biol. Chem. 290, 22880-22889 (2015).
130. Belzil V. V, et al. Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients. Brain Res. 1584, 15-21 (2014).
131. Liu E. Y, et al. C9orf72 hypermethylation protects against repeat expansion-Associated pathology in ALS/FTD. Acta Neuropathol 128 525-541 (2014).
132. McMillan C. T, et al. C9orf72 promoter hypermethylation is neuroprotective: neuroimaging and neuropathologic evidence. Neurology 84 1622-1630 (2015).
133. Russ J, et al. Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier. Acta Neuropathol. 129, 39-52 (2015).
134. Naumann A, Kraus C, Hoogeveen A, Ramirez C. M, & Doerfler W. Stable DNA methylation boundaries and expanded trinucleotide repeats: role of DNA insertions. J. Mol. Biol. 426, 2554-2566 (2014).
135. Simone R, Fratta P, Neidle S, Parkinson G. N, & Isaacs A. M. G quadruplexes: emerging roles in neurodegenerative diseases and the non-coding transcriptome. FEBS Lett 589 1653-1668 (2015).
136. Wang J, Haeusler A. R, & Simko E. A. Emerging role of RNA DNA hybrids in C9orf72 linked neurodegeneration. Cell Cycle. 14, 526-532 (2015).
137. Lin J, et al. Stabilization of G quadruplex DNA by C-5 methyl-cytosine in bcl 2 promoter: implications for epigenetic regulation. Biochem. Biophys. Res. Commun. 433, 368-373 (2013).
138. Brcic J, & Plavec J. Solution structure of a DNA quadruplex containing ALS and FTD related GGGGCC repeat stabilized by 8 bromodeoxyguanosine substitution. Nucleic Acids Res. 43, 8590-8600 (2015).
139. Wojciechowska M, Olejniczak M, Galka-Marciniak P, Jazurek M, & Krzyzosiak W. J. RAN translation and frameshifting as translational challenges at simple repeats of human neurodegenerative disorders. Nucleic Acids Res. 42, 11849-11864 (2014).
140. Colussi T. M, et al. Initiation of translation in bacteria by a structured eukaryotic IRES RNA. Nature. 519, 110-113 (2015).
141. Ren Q, et al. Alternative reading frame selection mediated by a tRNA-like domain of an internal ribosome entry site. Proc. Natl Acad. Sci. USA. 109, E630-E639 (2012).
142. Toulouse A, et al. Ribosomal frameshifting on MJD 1 transcripts with long CAG tracts. Hum. Mol. Genet. 14, 2649-2660 (2005).
143. Gaspar C, et al. CAG tract of MJD 1 may be prone to frameshifts causing polyalanine accumulation. Hum. Mol. Genet. 9, 1957-1966 (2000).
144. Davies J. E, & Rubinsztein D. C. Polyalanine and polyserine frameshift products in Huntingtons disease. J. Med. Genet. 43, 893-896 (2006).
145. Stochmanski S. J, et al. Expanded ATXN3 frameshifting events are toxic in Drosophila and mammalian neuron models. Hum. Mol. Genet. 21, 2211-2218 (2012).
146. Girstmair H, et al. Depletion of cognate charged transfer RNA causes translational frameshifting within the expanded CAG stretch in huntingtin. Cell Rep. 3, 148-159 (2013).
147. Yu C. H, Teulade-Fichou M. P, & Olsthoorn R. C. Stimulation of ribosomal frameshifting by RNA G quadruplex structures. Nucleic Acids Res. 42, 1887-1892 (2014).
148. Cammas A, et al. Stabilization of the G quadruplex at the VEGF IRES represses cap-independent translation. RNA Biol. 12, 320-329 (2015).